BioSpace News Archive

Diaceutics PLC, (AIM: DXRX), the precision diagnostic commercialization company, today announces research results from its COVID-19 oncology tracker, which shows the impact of the crisis on cancer testing and diagnosis in the US

International working group says the SF3B1 variant identifies a distinct disease entity, should inform WHO guidelines

Blue-Zone Technologies Ltd. (“Blue-Zone”) announces receipt from Health Canada of a Drug Identification Number (DIN) for DESFLURANE, USP, an important drug used for general anesthesia.

NCI to study PDS0103, in addition to planned Phase 2 clinical evaluation of PDS0101 in combination with other therapeutic agents

Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces financial results for the three months ended March 31, 2020.

Penumbra, Inc. announced that its management team is scheduled to present at the Bank of America Merrill Lynch 2020 Health Care Conference on Wednesday, May 13, 2020.

Jazz Pharmaceuticals plc announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic veno-occlusive disease post-hematopoietic stem-cell transplantation in high-risk or very high-risk patients is being discontinued.

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the United States Food and Drug Administration (FDA) Office of Orphan Products

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2020 financial results.

Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a virtual presentation at the BofA Securities 2020 Health Care Conference at 3:00 p.m. ET on Wednesday, May 13, 2020